Yoseph Shaaltiel, Executive VP, R&D at Protalix BioTherapeutics, Inc. (PLX), sold 100,000 shares at $4.95 ($509K) on 2009-07-06, disclosed to the SEC on 2009-07-08.
Scheduled sale ($509k) by Executive VP, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.95 | 20,000 | $99K | 19.4% |
| 2 | $5.13 | 80,000 | $410K | 80.6% |
| Total | $5.09 avg | 100,000 | $509K | 100% |
| Filing → |
| PLX | SELL | 2010-06-23 | $371K | — | Filing → |
| PLX | SELL | 2010-05-03 | $89K | — | Filing → |
| PLX | SELL | 2010-04-16 | $9K | — | Filing → |